Canadian parents support vaccinating boys in publicly funded programs
B-roll available at:
KIRKLAND, QC, April 18, 2013 /CNW Telbec/ - Today, Prince Edward Island became
the first province in Canada to extend its publicly funded school-based HPV
vaccination program to boys. The program will use GARDASIL(®) [Quadrivalent
Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine], the only HPV
vaccine indicated and recommended for boys and men.
In 2007, The National Advisory Committee on Immunization (NACI) recommended
the quadrivalent HPV vaccine to protect Canadian girls and women aged 9 to 26
against a broad spectrum of HPV-related diseases. In 2012, NACI updated and
strengthened its statement related to the use of HPV vaccines and recommended
the use of the quadrivalent HPV vaccine in males between 9 to 26 years of
"PEI was one of the first provinces to follow NACI's recommendations by
introducing school-based HPV vaccination programs to girls in 2007. PEI's
decision to include boys is an important milestone in protecting both males
and females against the diseases that can result from HPV infection such as
genital warts and anal-genital cancers," said Dr. Mauricio Ede, Medical
Director, Medical Affairs at Merck Canada. "Both males and females contribute
to the spread of HPV and both develop diseases as a result of HPV infection."
More recently, The Canadian Medical Association adopted a resolution that
calls for public funding to vaccinate both girls and boys for human
A national survey conducted in March 2011 by Ipsos Reid(3), commissioned by
Merck, showed that:
-- 85% of parents of males would allow their son to get vaccinated
against HPV if it was offered through a publicly-funded program
at his school
-- 88% of parents support the assertion that boys should be
vaccinated against HPV in the same program as girls
-- 91% of parents agree that vaccinating both boys and girls
against HPV would provide greater protection than vaccinating
Australia, a country to which Canada is often compared, extended its national
school-based HPV vaccination program to boys aged 12-13, earlier this year. It
includes a catch-up program for 14 to 15 year-olds until the end of the 2014
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada. Through
our medicines, vaccines, biologic therapies, and consumer and animal products,
we work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to increasing
access to healthcare through far-reaching policies, programs and partnerships.
For more information about our operations in Canada, visit www.merck.ca.
Forward Looking Statement
This news release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck's management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck's ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck's
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck's 2011
Annual Report on Form 10-K and the company's other filings with the Securities
and Exchange Commission (SEC) available at the SEC's Internet site
The news release is available at www.cnw.ca.
(1) Public Health Agency of Canada Web site. Accessed at:
(2 )The Canadian Medical Association Web site. Accessed at:
resolutions/2012GC-Resolutions_en.pdf. See pg 4 resolution 47.
(3) Ipsos Reid factum issued on January 19, 2012. Accessed at:
(4) Australian Government, Department of Health and Ageing Web site. Available
Sheila Murphy Merck 514-428-2748
Quebec Roch Landriault NATIONAL Public Relations 514-843-2345
Alberta Dan Brennan NATIONAL Public Relations 403-690-4556
SOURCE: Merck Canada Inc.
To view this news release in HTML formatting, please use the following URL:
CO: CNW Enriched News Releases
ST: Prince Edward Island
NI: MTC * HEA
-0- Apr/18/2013 18:21 GMT
Press spacebar to pause and continue. Press esc to stop.